Absolutely. This was the first FDA-approved indication for Optune. Although it was approved in 2011, one could say that it never really "caught on." I personally did not start using it or recommending it until the second FDA approved indication (for upfront first-line treatment) appeared around...

Yes our team offers TTF to  patients with recurrent GBM.  EF-11 compared TTF to conventional chemotx (mostly nitrosurea-based) in this pt population and found comparable OS but far fewer toxicities and better QOL with TTF.  In general, for bev-naive recurrent GBMs, our team tends to f...